Cloud-Based Multicenter Data Collection and Epidemiologic Analysis of Bisphosphonate-Related Osteonecrosis of the Jaws in a Central European Population
Abstract
:1. Introduction
2. Materials and Methods
- (1)
- Previous or current BP treatment regardless of drug type, dose, or route of administration;
- (2)
- Consecutive or concomitant BP treatment with different bisphosphonate agents;
- (3)
- Intra- or extraoral lesion following or after bisphosphonate therapy.
3. Results
3.1. Sex Ratio
3.2. Underlying Disease
3.3. Age
3.4. Comorbidity
3.5. Route of Administration and Type of Bisphosphonate
3.6. Presumed Triggering Factors
3.7. Localization of the Osteonecrosis
3.8. Staging
4. Discussion
Author Contributions
Funding
Conflicts of Interest
References
- Marx, R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral Maxillofac. Surg. 2003, 61, 1115–1117. [Google Scholar] [CrossRef]
- Ruggiero, S.L.; Mehrotra, B.; Rosenberg, T.J.; Engroff, S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J. Oral Maxillofac. Surg. 2004, 62, 527–534. [Google Scholar] [CrossRef] [PubMed]
- Srinivasan, D.; Shetty, S.; Ashworth, D.; Grew, N.; Millar, B. Orofacial pain—A presenting symptom of bisphosphonate associated osteonecrosis of the jaws. Br. Dent. J. 2007, 203, 91–92. [Google Scholar] [CrossRef] [PubMed]
- Marx, R.E.; Sawatari, Y.; Fortin, M.; Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 2005, 63, 1567–1575. [Google Scholar] [CrossRef]
- Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws. Force American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2007, 65, 369–376. [Google Scholar] [CrossRef]
- Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral Maxillofac. Surg. 2014, 72, 1938–1956. [Google Scholar] [CrossRef]
- Ruggiero, S.L.; Dodson, T.B.; Assael, L.A.; Landesberg, R.; Marx, R.E.; Mehrotra, B. AAOMS Position Paper BRONJ American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update. J. Oral Maxillofac. Surg. 2009, 67 (Suppl. 1), 2–12. [Google Scholar] [CrossRef]
- Rosella, D.; Papi, P.; Giardino, R.; Cicalini, E.; Piccoli, L.; Pompa, G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J. Int. Soc. Prev. Community Dent. 2016, 6, 97–104. [Google Scholar] [CrossRef] [Green Version]
- Abu-Id, M.H.; Warnke, P.H.; Gottschalk, J.; Springer, I.; Wiltfang, J.; Yahya, A.C.; Russo, P.A.; Kreusch, T. “Bis-phossy jaws”—High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J. Craniomaxillofac. Surg. 2008, 36, 95–103. [Google Scholar] [CrossRef]
- Ristow, O.; Gerngroß, C.; Schwaiger, M.; Hohlweg-Majert, B.; Kehl, V.; Jansen, H.; Hahnefeld, L.; Otto, S.; Pautke, C. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis? J. Oral Maxillofac. Surg. 2014, 72, 903–910. [Google Scholar] [CrossRef]
- Otto, S.; Tröltzsch, M.; Jambrovic, V.; Panya, S.; Probst, F.; Ristow, O.; Ehrenfeld, M.; Pautke, C. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J. Craniomaxillofac. Surg. 2015, 43, 847–854. [Google Scholar] [CrossRef] [PubMed]
- Ziebart, T.; Halling, F.; Heymann, P.; Neff, A.; Blatt, S.; Jung, J.; Pabst, A.; Righesso, L.; Walter, C. Impact of Soft Tissue Pathophysiology in the Development and Maintenance of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). Dent. J. (Basel) 2016, 4, 36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Otto, S.; Hafner, S.; Mast, G.; Tischer, T.; Volkmer, E.; Schieker, M.; Stürzenbaum, S.R.; von Tresckow, E.; Kolk, A.; Ehrenfeld, M.; et al. Bisphosphonate-related osteonecrosis of the jaw: Is pH the missing part in the pathogenesis puzzle? J. Oral Maxillofac. Surg. 2010, 68, 1158–1161. [Google Scholar] [CrossRef]
- Ruggiero, S.L. Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin. Cases Miner Bone Metab. 2007, 4, 37–42. [Google Scholar]
- Migliorati, C.A.; Casiglia, J.; Epstein, J.; Jacobsen, P.L.; Siegel, M.A.; Woo, S.B. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J. Am. Dent. Assoc. 2005, 136, 1658–1668. [Google Scholar] [CrossRef] [Green Version]
- Ramaglia, L.; Guida, A.; Iorio-Siciliano, V.; Cuozzo, A.; Blasi, A.; Sculean, A. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: A systematic review and meta-analysis of the drug suspension protocol. Clin. Oral Investig. 2018, 22, 597–615. [Google Scholar] [CrossRef]
- Di Fede, O.; Bedogni, A.; Giancola, F.; Saia, G.; Bettini, G.; Toia, F.; D’Alessandro, N.; Firenze, A.; Matranga, D.; Fedele, S.; et al. BRONJ in patients with rheumatoid arthritis: A multicenter case series. Oral Dis. 2016, 22, 543–548. [Google Scholar] [CrossRef] [Green Version]
- Kos, M.; Kuebler, J.F.; Luczak, K.; Engelke, W. Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk. J. Craniomaxillofac. Surg. 2010, 38, 255–259. [Google Scholar] [CrossRef]
- Diniz-Freitas, M.; López-Cedrún, J.L.; Fernández-Sanromán, J.; García-García, A.; Fernández-Feijoo, J.; Diz-Dios, P. Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain. Med. Oral Patol. Oral Cir. Bucal. 2012, 17, 751–758. [Google Scholar] [CrossRef]
- Nomura, T.; Shibahara, T.; Uchiyama, T.; Yamamoto, N.; Shibui, T.; Yakushiji, T.; Watanabe, A.; Muramatsu, K.; Ogane, S.; Murayama, M.; et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: A case series of 13 patients at our clinic. Bull Tokyo Dent. Coll. 2013, 54, 117–125. [Google Scholar] [CrossRef] [Green Version]
- Andriani, A.; Petrucci, M.T.; Caravita, T.; Montanaro, M.; Villivà, N.; Levi, A.; Siniscalchi, A.; Bongarzoni, V.; Pisani, F.; De Muro, M. Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom’s macroglobulinemia: A retrospective multicentric study. Blood Cancer J. 2012, 2, 62. [Google Scholar] [CrossRef] [PubMed]
- Vescovi, P.; Campisi, G.; Fusco, V.; Mergoni, G.; Manfredi, M.; Merigo, E.; Solazzo, L.; Gabriele, M.; Gaeta, G.M.; Favia, G. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011, 47, 191–194. [Google Scholar] [CrossRef] [PubMed]
- Schubert, M.; Klatte, I.; Linek, W.; Müller, B.; Döring, K.; Eckelt, U.; Hemprich, A.; Berger, U.; Hendricks, J. The saxon bisphosphonate register—Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. Oral Oncol. 2012, 48, 349–354. [Google Scholar] [CrossRef]
- Capalbo, S.; Franzese, M.G.; Palumbo, G. Osteonecrosis of the myeloma patients treated with bisphosphonates. Clin. Cases Miner. Bone Metab. 2007, 4, 43–47. [Google Scholar]
- Graziani, F.; Vescovi, P.; Campisi, G.; Favia, G.; Gabriele, M.; Gaeta, G.M.; Gennai, S.; Goia, F.; Miccoli, M.; Peluso, F. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: A retrospective survey of 347 cases. J. Oral Maxillofac. Surg. 2012, 70, 2501–2507. [Google Scholar] [CrossRef]
- Thumbigere-Math, V.; Tu, L.; Huckabay, S.; Dudek, A.Z.; Lunos, S.; Basi, D.L.; Hughes, P.J.; Leach, J.W.; Swenson, K.K.; Gopalakrishnan, R. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am. J. Clin. Oncol. 2012, 35, 386–392. [Google Scholar] [CrossRef]
- Gabbert, T.I.; Hoffmeister, B.; Felsenberg, D. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J. Cancer Res. Clin. Oncol. 2015, 141, 4. [Google Scholar] [CrossRef]
- Mavrokokki, T.; Cheng, A.; Stein, B. Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia. J. Oral Maxillofac. Surg. 2007, 65, 415–423. [Google Scholar] [CrossRef]
- McGowan, K.; Ivanovski, S.; Acton, C. Osteonecrosis of the jaws: A 14-year retrospective survey of hospital admissions. Aust. Dent. J. 2018, 63, 202–207. [Google Scholar] [CrossRef] [Green Version]
- Ghidini, G.; Manfredi, M.; Giovannacci, I.; Mergoni, G.; Sarraj, A.; Mureddu, M.; Giunta, G.; Bonanini, M.; Meleti, M.; Vescovi, P. Medication-related osteonecrosis of the jaw: Risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs. Minerva Stomatol. 2017, 66, 135–140. [Google Scholar] [CrossRef]
- Vandone, A.M.; Donadio, M.; Mozzati, M.; Ardine, M.; Polimeni, M.A.; Beatrice, S.; Ciuffreda, L.; Scoletta, M. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience. Ann. Oncol. 2012, 23, 193–200. [Google Scholar] [CrossRef] [PubMed]
- Chaurand-Lara, J.; Pacheco-Ruiz, L.; Trejo-Campos, J.L.; Facio-Umaña, J.A.; Mora-Pérez, J. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: A retrospective cohort study. Cir. Cir. 2019, 87, 396–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gliklich, R.; Wilson, J. Epidemiology of Bisphosphonate-Related Osteonecrosis of the Jaws: The Utility of a National Registry. J. Oral Maxillofac. Surg. 2009, 67, 71–74. [Google Scholar] [CrossRef] [PubMed]
- Otto, S.; Schreyer, C.; Hafner, S.; Mast, G.; Ehrenfeld, M.; Stürzenbaum, S.; Pautke, C. Bisphosphonate-related osteonecrosis of the jaws—Characteristics, risk factors, clinical features, localization and impact on oncological treatment. J. Craniomaxillofac. Surg. 2012, 40, 303–309. [Google Scholar] [CrossRef]
- Pazianas, M.; Miller, P.; Blumentals, W.A.; Bernal, M.; Kothawala, P.A. Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics. Clin. Ther. 2007, 29, 1548–1558. [Google Scholar] [CrossRef]
- Bamias, A.; Kastritis, E.; Bamia, C.; Moulopoulos, L.A.; Melakopoulos, I.; Bozas, G.; Koutsoukou, V.; Gika, D.; Anagnostopoulos, A.; Papadimitriou, C. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J. Clin. Oncol. 2005, 2, 8580–8587. [Google Scholar] [CrossRef]
- Rogers, S.N.; Palmer, N.O.; Lowe, D.; Randall, C. United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. Br. J. Oral Maxillofac. Surg. 2015, 53, 176–182. [Google Scholar] [CrossRef]
- Yuh, D.Y.; Chang, T.H.; Huang, R.Y.; Chien, W.C.; Lin, F.G.; Fu, E. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan. J. Dent. 2014, 42, 1343–1352. [Google Scholar] [CrossRef]
- Schiodt, M.; Vadhan-Raj, S.; Chambers, M.S.; Nicolatou-Galitis, O.; Politis, C.; Coropciuc, R.; Fedele, S.; Jandial, D.; Zhang, J.; Ma, H. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Supportive Care Cancer 2018, 26, 1905–1915. [Google Scholar] [CrossRef] [Green Version]
- Fung, P.; Bedogni, G.; Bedogni, A.; Petrie, A.; Porter, S.; Campisi, G.; Bagan, J.; Fusco, V.; Saia, G.; Acham, S. Time to onset of bisphosphonate-related osteonecrosis of the jaws: A multicentre retrospective cohort study. Oral Dis. 2017, 23, 477–483. [Google Scholar] [CrossRef]
- Otto, S.; Abu-Id, M.H.; Fedele, S.; Warnke, P.H.; Becker, S.T.; Kolk, A.; Mücke, T.; Mast, G.; Köhnke, R.; Volkmer, E.; et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence—A multi-centre study. J. Craniomaxillofac. Surg. 2011, 39, 272–277. [Google Scholar] [CrossRef] [PubMed]
- Ehrenstein, V.; Nielsen, H.; Pedersen, A.B.; Johnsen, S.P.; Pedersen, L. Clinical epidemiology in the era of big data: New opportunities, familiar challenges. Clin. Epidemiol. 2017, 9, 245–250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Definition of Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) (AAOMS 2009) | Definition of MRONJ (AAOMS 2014) |
---|---|
1. Current or previous treatment with a bisphosphonate; 2. Exposed bone in the maxillofacial region that has persisted for more than eight weeks; 3. No history of radiation therapy to the jaws. | 1. Current or previous treatment with antiresorptive or antiangiogenic agents; 2. Exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than eight weeks; 3. No history of radiation therapy to the jaws or obvious metastatic disease to the jaws. |
|
Number | Female | Male | |||
---|---|---|---|---|---|
Vereb et al. | 180 | 122 | 67.8% | 58 | 32.2% |
Otto 2012 | 126 | 92 | 73.0% | 34 | 27.0% |
Diniz-Freitas 2012 | 20 | 19 | 95% | 1 | 5% |
Schubert 2011 | 258 | 175 | 67.8% | 83 | 32.2% |
Kos 2010 | 34 | 19 | 55.9% | 15 | 44.1% |
Mavrokokki 2007 | 114 | 63 | 55% | 51 | 45% |
Summary | 732 | 490 | 66.9% | 242 | 33.1% |
Underlying Disease | n | Mean | Min | Max | SD | |
---|---|---|---|---|---|---|
Malignant | Breast cc. | 66 | 64.68 | 37 | 85 | 10.16 |
Prostate cc. | 30 | 71.57 | 61 | 89 | 7.00 | |
Multiple myeloma | 16 | 67.62 | 57 | 80 | 6.09 | |
Renal cc. | 13 | 62.92 | 51 | 77 | 8.45 | |
Lung cc. | 7 | 65.00 | 48 | 81 | 10.77 | |
Gastrointestinal cc. | 5 | 66.80 | 54 | 80 | – | |
Other | 3 | 62.00 | 53 | 75 | – | |
Total malignant | 140 | 66.32 | 37 | 89 | 9.43 | |
Benign | Osteoporosis | 34 | 70.31 | 42 | 84 | 9.79 |
Rheumatoid arthritis | 2 | 39 | 38 | 40 | – | |
Total benign | 36 | 68.57 | 38 | 84 | – | |
Summary | 176 | 66.80 | 37 | 89 | – |
Oral Bisphosphonate | Benign Diseases | Malignant Diseases | Summary |
---|---|---|---|
aledronate | 17 | 1 | 18 |
ibadronate | 2 | 17 | 19 |
clodronate | 4 | 5 | 9 |
risedronate | 6 | – | 6 |
Summary | 29 | 23 | 52 |
Number of Bisphosphonate Infusions | Zoledronate (Combined) | Zoledronate (Single) | Ibandronate | Pamidronate |
---|---|---|---|---|
1–6 x | – | 29 | – | – |
7–12 x | 1 | 17 | 5 | – |
13–18 x | – | 11 | 1 | – |
19–24 x | 3 | 12 | 3 | – |
25–30 x | 1 | 6 | 1 | – |
31–36 x | – | 7 | – | – |
37–42 x | – | 2 | – | – |
43–48 x | – | 6 | 1 | – |
>48 x | 1 | 20 | – | 1 |
Summary | 6 | 110 | 11 | 1 |
Staging | Total | |||
---|---|---|---|---|
Stage 1 | Stage 2 | Stage 3 | ||
Intravenous | 14 | 57 | 35 | 106 |
13.2% | 53.8% | 33.0% | 100.0% | |
Both | 7 | 11 | 4 | 22 |
31.8% | 50.0% | 18.2% | 100.0% | |
Oral | 15 | 28 | 9 | 52 |
28.8% | 53.8% | 17.3% | 100.0% | |
Total | 36 | 96 | 48 | 180 |
20.0% | 53.3% | 26.7% | 100.0% |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vereb, T.; Boda, K.; Czakó, L.; Vaszilkó, M.; Fülöp, G.; Klenk, G.; Janovszky, Á.; Oberna, F.; Piffkó, J.; Seres, L. Cloud-Based Multicenter Data Collection and Epidemiologic Analysis of Bisphosphonate-Related Osteonecrosis of the Jaws in a Central European Population. J. Clin. Med. 2020, 9, 426. https://doi.org/10.3390/jcm9020426
Vereb T, Boda K, Czakó L, Vaszilkó M, Fülöp G, Klenk G, Janovszky Á, Oberna F, Piffkó J, Seres L. Cloud-Based Multicenter Data Collection and Epidemiologic Analysis of Bisphosphonate-Related Osteonecrosis of the Jaws in a Central European Population. Journal of Clinical Medicine. 2020; 9(2):426. https://doi.org/10.3390/jcm9020426
Chicago/Turabian StyleVereb, Tamás, Krisztina Boda, László Czakó, Mihály Vaszilkó, Gábor Fülöp, Gusztáv Klenk, Ágnes Janovszky, Ferenc Oberna, József Piffkó, and László Seres. 2020. "Cloud-Based Multicenter Data Collection and Epidemiologic Analysis of Bisphosphonate-Related Osteonecrosis of the Jaws in a Central European Population" Journal of Clinical Medicine 9, no. 2: 426. https://doi.org/10.3390/jcm9020426
APA StyleVereb, T., Boda, K., Czakó, L., Vaszilkó, M., Fülöp, G., Klenk, G., Janovszky, Á., Oberna, F., Piffkó, J., & Seres, L. (2020). Cloud-Based Multicenter Data Collection and Epidemiologic Analysis of Bisphosphonate-Related Osteonecrosis of the Jaws in a Central European Population. Journal of Clinical Medicine, 9(2), 426. https://doi.org/10.3390/jcm9020426